GLP-1s and your heart: what the cardiovascular evidence shows

For years, the case for treating excess weight medically rested on an inference: carrying less weight should mean less heart disease eventually. That inference is no longer the whole story. A GLP-1 medication has now been shown, in a large randomized trial, to directly reduce heart attacks, strokes, and cardiovascular death. For anyone weighing whether these medications are worth the cost and the side effects, the heart data is arguably the most important evidence to understand.

Why the heart is part of the weight conversation

Excess weight is one of the strongest drivers of cardiovascular disease. It raises blood pressure, worsens cholesterol, promotes inflammation, and pushes the body toward insulin resistance, all of which damage arteries over time. The American Heart Association treats obesity as a major modifiable risk factor for heart disease for exactly these reasons. What was missing until recently was proof that treating weight with medication actually interrupts that chain of events, rather than just improving the numbers on a lab report.

What the SELECT trial actually found

The study that changed the conversation is called SELECT, published in the New England Journal of Medicine in 2023. It enrolled more than 17,000 adults who had overweight or obesity plus established cardiovascular disease, meaning a prior heart attack, stroke, or peripheral artery disease, but who did not have diabetes. Half received weekly semaglutide at the 2.4 mg weight-management dose, half received placebo, and everyone was followed for roughly three years on average.

The result: the semaglutide group had a 20 percent lower rate of major adverse cardiovascular events, the composite of heart attack, stroke, and death from cardiovascular causes. That is a large effect for a prevention trial, in the same territory as statins and blood pressure treatment, and it was achieved in people already receiving standard cardiac care. This was not a study of surrogate markers. Fewer people had heart attacks. Fewer people died of cardiovascular causes.

The FDA indication that followed

Regulators found the evidence convincing. In March 2024 the FDA approved semaglutide 2.4 mg to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight. That made it the first weight-management medication with an approved cardiovascular prevention indication. The practical significance is bigger than the label itself: an official indication reframes the drug from a cosmetic or lifestyle product into cardiac prevention, which is a different conversation with insurers, with clinicians, and frankly with skeptical family members.

Is it the weight loss, or the drug?

Here is the detail researchers found most interesting: the curves separating semaglutide from placebo began to diverge within months, well before participants reached their full weight loss. That timing suggests the benefit is not purely a downstream effect of a smaller number on the scale. GLP-1 medications also reduce inflammation, lower blood pressure, and improve cholesterol and blood sugar, and some of those effects arrive early. The honest answer is that the benefit is probably a blend of the weight loss and direct effects of the drug, in proportions still being worked out. Either way, the markers involved are the same ones worth tracking on any medically supervised program, which is why the metabolic health markers that matter more than the scale deserve as much attention as your weight graph.

Who this evidence applies to, and who it does not

Precision matters here. SELECT studied people who already had cardiovascular disease, so the 20 percent risk reduction is proven in that group, called secondary prevention. If you have overweight or obesity but no history of heart disease, the trial does not directly answer your question, though the improvements in blood pressure, lipids, and inflammation give reasonable grounds for optimism while primary prevention research continues. The finding also does not turn these medications into something everyone should take; the qualifying criteria, health evaluation, and supervision described in who actually qualifies for a GLP-1 still apply. For people with heart disease who do qualify, however, the calculus genuinely shifted: the medication is no longer only about weight.

What it means for cost and coverage

The cardiovascular indication has practical financial consequences. Medicare, which is barred from covering drugs prescribed solely for weight loss, can cover semaglutide when it is prescribed for cardiovascular risk reduction in people who meet the SELECT-style criteria, and some commercial plans have followed the same logic. Coverage remains inconsistent and prior authorization is common, so the strategies in navigating GLP-1 insurance and cost still matter, but patients with documented heart disease now have a stronger case to make than they did before 2024.

The takeaway

The SELECT trial showed that weekly semaglutide reduced heart attacks, strokes, and cardiovascular death by 20 percent in adults with existing heart disease and excess weight, and the FDA has approved it for that use. The benefit appears to come from both the weight loss and direct effects of the medication, it is proven for people who already have cardiovascular disease, and it has begun to change insurance coverage. If you have a cardiac history and have been undecided about medical weight treatment, this evidence belongs in the conversation with your cardiologist and your prescriber. This is general information, not medical advice; treatment decisions belong to you and your clinicians together.

Related reading: The metabolic health markers that matter more than the scale.